Selected publications to 3D microtumor technology
SLAS Discov. 2020 Mar;25(3):265-276
A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells.
Weydert Z, Lal-Nag M, Mathews-Greiner L, Thiel C, Cordes H, Küpfer L, Guye P, Kelm JM, Ferrer M.
Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline.
Kelm JM, Lal-Nag M, Sittampalam GS, Ferrer M.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.
Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types.
Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK.
Relevant publications about functional drug profiling
Functional precision cancer medicine-moving beyond pure genomics.
Letai A.
Lancet Haematol. 2017 Dec;4(12):e595-e606.
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies.
Berend Snijder et. al.
References on molecular guided precision medicine
Cancer Discov. 2017 Aug;7(8):818-831.
AACR Project GENIE: Powering Precision Medicine through an International Consortium.
AACR Project GENIE Consortium.
Lancet Oncol. 2015 Oct;16(13):1324-34.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA).
Christophe Le Tourneau et. al.
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J, Chen EY, Prasad V
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Haslam A, Prasad V